Apac
  • Home
  • CXO Insights
  • CIO Views
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • About us
Apac
  • Admired Tech

    Agile

    AI Healthcare

    Artificial Intelligence

    Augmented Reality

    Aviation

    Big Data

    Blockchain

    Cloud

    Cryptocurrency

    Cyber Security

    Digital Transformation

    Drone

    HPC

    Infrared

    Internet of Things

    Networking

    PropTech

    Remote Work

    Scheduling Software

    Simulation

    Startup

    Storage

    Wireless

  • Banking

    E-Commerce

    Education

    FinTech

    Food and Beverages

    Healthcare

    Insurance

    Legal

    Manufacturing

    Pharma and Life Science

    Retail

    Travel and Hospitality

  • CISCO

    Microsoft

    Oracle

    Salesforce

    SAP

    ServiceNow

  • Business Intelligence

    CEM

    Cloud-based Planning

    Cognitive

    Compliance

    Contact Center

    Contact Tracing

    Contactless Payments

    Corporate Finance

    CRM

    Custom Software Development

    Data Center

    Enterprise Architecture

    Enterprise Communications

    Enterprise Contract Management

    Field Service

    HR Technology

    IT Service Management

    Managed Services

    Procurement

    Product Management

    RegTech

    Revenue Management

Menu
    • CISCO
    • Collaboration
    • Compliance
    • Contact Center
    • Healthcare
    • IT Service Management
    • Microsoft
    • Retail
    • MORE
    #

    Apac CIO Outlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIO Outlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    • Home
    • News
    • Biotech
    Editor's Pick (1 - 4 of 8)
    left
    Framework of Three Horizons to Manage Current and Future Growth

    Clark Golestani, VP & CIO, Merck

    The Changing Role of CIO in the Biopharmaceutical Industry

    Andy Newsom, CIO, CSL Behring

    Formula Five For Biotech IT

    Jeffrey Keisling, CIO and SVP, Pfizer

    Finding Answers in R&D Data is a Team Sport

    Dan Hausman,

    Plant Biotechnology Success Requires Collaboration, Proactive Strategy

    Tim Hassinger, President and CEO, Dow AgroSciences

    The Biotech IT PMO 2.0

    Paul Ritchie,

    The Biotech CIO Roadmap in a Sea of Change

    Amit Shah, VP of IT- Enterprise Applications & Systems, Excelitas Technologies

    The Internet of Things in Healthcare:Smart Strategies to Deliver Better Value

    Miguel Louzan, VP-IT, UCB, Inc.

    right

    Iaso Biotherapeutics Bags $60M in Series B Round of Financing

    By Apac CIO Outlook | Monday, April 27, 2020
    Tweet

    Iaso Biotherapeutics secures $60M funding for the expansion of its product pipeline 

    FREMONT, CA: Iaso Biotherapeutics, a leading Nanjing, China-based clinical-stage biotechnology company, secures funding worth $60 million from its Series B round of Financing. GL Ventures led the Series B round. 

    The clinical-stage biotechnology company focuses the fund utilization mainly on the expansion of its product pipeline and enhancing the progress rate of the current projects ( including the regulatory applications and clinical trials in China and the US). It also aims further to advance the technology of a fully-human antibody development platform, encourage co-operations with international research and development institutions, and accelerate the development of commercial facilities. 

    From its inception in 2017, Iaso Biotherapeutics has been a clinical-stage biotechnology company that was dedicated wholly to the development of innovative cell therapies to cure cancer. The company is simultaneously developing more than ten pipeline products, focusing more on autologous and universal CAR-T products for hematological tumors. All products of the company are based on the fully human sequence. Additional development efforts comprise of unique TCR-like CAR-T cell therapy products for solid tumor indications such as viral infection related gastric cancer and nasopharyngeal carcinoma. 

    Iaso Bio also owns a proprietary phage display library(>2×1011) that supports the demand for fully-human antibodies necessary for CAR-T and lays the foundational for the development of antibody-drug pipelines as well. The company's in-house plasmid, lentivirus, and CAR-T production technology platforms fulfill the requirements of IND submissions and clinical research for numerous products. In 2019, September, the company obtained the NMPA approval of phase lb/II IND application for CT103A, an anti-BCMA CAR-T co-developed in association with Innovent Biologics for treating the relapsed refractory multiple myeloma (rr/mm). Additionally, many new drug candidates have entered the pre-clinical stage or are involved in investigator-initiated clinical trials with various drugs expected to enter clinical trials in the next few years. 

    Check out: Top Bioinformatics Solution Companies

    tag

    Biotechnology

    Bioinformatics

    Oncology

    Weekly Brief

    loading
    ON THE DECK

    Content Management System 2020

    Top Vendors

    Contactless Payments 2020

    Top Vendors

    Admired Tech 2020

    Top Vendors

    Previous Next

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Read Also

    How Credible is Cloud Storage Security?

    How Credible is Cloud Storage Security?

    How Internet of Medical Things Changing the Facets of Healthcare

    How Internet of Medical Things Changing the Facets of Healthcare

    IoT and the Challenges it Faces

    IoT and the Challenges it Faces

    Key Advantages of Cloud Computing

    Key Advantages of Cloud Computing

    Five Best Practices of Implementing ITSM

    Five Best Practices of Implementing ITSM

    Three Significant Benefits of Blockchain in Healthcare

    Three Significant Benefits of Blockchain in Healthcare

    Loading...

    Copyright © 2021 APAC CIOoutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy Policy  |  Sitemap |  Subscribe

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/iaso-biotherapeutics-bags-60m-in-series-b-round-of-financing--nwid-7424.html